MAPT and Alzheimer disease: Recent advances in tau-PET imaging have drastically improved the detection of tau in the secondary 3/4R tauopathy AD, which has transformed biomarker-based diagnosis, staging, prognosis and treatment monitoring in AD [11, 12].